Related Experiment Video
Updated: May 5, 2026
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 19, 2013
17.5K
Intensive chemotherapy for acute myelogenous leukemia
Annals of Internal Medicine
|June 1, 1981
Summary
High-dose induction chemotherapy (TAD) achieved an 82% remission rate in acute myelogenous leukemia (AML) patients. However, maintenance strategies including immunotherapy did not prolong remission duration or improve survival outcomes.
Area of Science:
- Oncology
- Hematology
- Clinical Trials
Background:
- Acute myelogenous leukemia (AML) is a serious hematologic malignancy.
- Effective induction chemotherapy is crucial for achieving remission in AML patients.
Purpose of the Study:
- To evaluate the efficacy of a high-dose induction chemotherapy regimen (TAD) in AML.
- To assess the impact of consolidation and maintenance chemotherapy, with or without immunotherapy, on remission duration and survival.
Main Methods:
- A group of 68 AML patients received a 7-day TAD induction chemotherapy course.
- Patients achieving remission underwent consolidation chemotherapy and were randomized for maintenance therapy (with or without immunotherapy).
- Remission duration and survival rates were analyzed.
Main Results:
- An 82% complete remission rate was observed with TAD induction chemotherapy.
- Median remission duration was 13 months and median survival was 21 months.
- Neither central nervous system prophylaxis nor immunotherapy maintenance prolonged remission or survival.
Conclusions:
- Intensive induction chemotherapy (TAD) is effective in achieving high remission rates for AML.
- Current maintenance strategies, including immunotherapy, have limited success in prolonging remission or survival.
- Further research is needed to improve long-term outcomes for AML patients.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
820
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
820